Table 1.
Relationship between the expression of GRO-β and clinicopathological characteristics in ovarian cancer.
| Characteristic | n | Low or no expression | High expression | Pearson χ 2 | P value |
|---|---|---|---|---|---|
| Total | 136 | 61 | 75 | ||
| Age | 2.051 | 0.152 | |||
| ≤60 | 94 | 46 (48.94) | 48 (51.06) | ||
| >60 | 42 | 15 (35.71) | 27 (64.29) | ||
| Histological type | 1.176 | 0.555 | |||
| Serous | 89 | 37 (41.57) | 52 (58.43) | ||
| Endometrioid | 13 | 7 (53.85) | 6 (46.15) | ||
| Others | 34 | 17 (50.00) | 17 (50.00) | ||
| Differentiation | 1.083 | 0.298 | |||
| Low | 28 | 15 (53.57) | 13 (46.43) | ||
| High | 108 | 46 (42.59) | 62 (57.41) | ||
| FIGO stage | 4.593 | 0.032∗ | |||
| I~II | 80 | 42 (52.50) | 38 (47.50) | ||
| III~IV | 56 | 19 (33.93) | 37 (66.07) | ||
| CEA level | 1.636 | 0.201 | |||
| ≤5 | 80 | 34 (42.50) | 46 (57.50) | ||
| >5 | 13 | 8 (61.54) | 5 (38.46) | ||
| Unknown | 43 | 19 | 24 | ||
| CA19-9 level | 0.053 | 0.817 | |||
| ≤37 | 70 | 32 (45.71) | 38 (54.29) | ||
| >37 | 21 | 9 (42.86) | 12 (57.14) | ||
| Unknown | 45 | 20 | 25 | ||
| CA125 level | 0.853 | 0.355 | |||
| ≤35 | 12 | 4 (33.33) | 8 (66.67) | ||
| >35 | 82 | 39 (47.56) | 43 (52.44) | ||
| Unknown | 42 | 18 | 24 | ||
| CA153 level | 1.457 | 0.227 | |||
| ≤31 | 38 | 20 (52.63) | 18 (47.37) | ||
| >31 | 48 | 19 (39.58) | 29 (60.42) | ||
| Unknown | 50 | 22 | 28 | ||
| SF level | 2.686 | 0.101 | |||
| ≤204 | 59 | 30 (50.85) | 29 (49.15) | ||
| >204 | 28 | 9 (32.14) | 19 (67.86) | ||
| Unknown | 49 | 22 | 27 | ||
| Ascites | 4.916 | 0.027∗ | |||
| No | 48 | 26 (54.17) | 22 (45.83) | ||
| Yes | 42 | 13 (30.95) | 29 (69.05) | ||
| Unknown | 46 | 22 | 24 | ||
| Lymph node and other metastases | 26.097 | <0.001∗ | |||
| No | 60 | 37 (61.67) | 23 (38.33) | ||
| Yes | 76 | 24 (31.58) | 52 (68.42) |
∗ P < 0.05.
Others: clear cell, nine cases; mucinous, seven cases; transitional cell, six cases; mixed, 12 cases.